Advanced searches left 3/3

Amyotrophic Lateral Sclerosis - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 27 June 2022

* If you want to update the article please login/register

Cultivating Self-Compassion Course for Persons Living With Amyotrophic Lateral Sclerosis

ALS multidisciplinary care emphasizes the importance of treating people with ALS' psychological needs and well-being, so doing research into ALS interventions that address people with ALS is a primary goal. According to recent reports, mindfulness-based interventions improve the quality of life for people with ALS. Very few studies have compared mindfulness-based approaches in the ALS population, and no research has yet looked at self-compassion people with ALS. Compassion pALS will be developed from the Mindful Self-Compassion Program to include ALS clinical characteristics and minimize potential barriers to participation. Secondary outcomes include Secondary outcome measures, Patient Health Questionnaire-9, Amyotrophic Lateral Sclerosis Functional Rating Scale-R, Feasibility of Intervention Measures, Acceptability of Intervention Measure, and Intervention Appropriateness Measure.

Source link: https://clinicaltrials.gov/ct2/show/NCT05202743


Natural History and Biomarkers of C9ORF72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Objective This research is intended to illustrate the natural history of disease in patients with a repeat mutation in the C9ORF72 gene, which causes amyotrophic lateral sclerosis and frontotemporal dementia. 62 individuals with a confirmed repeat increase in the C9ORF72 gene who have ALS, ALS-FTD, or FTD, or those who are carriers of the gene mutation and have a symptomatic family member are among the study sample 62 people with a documented repeat expansion. The ALS Functional rating scale, which has been updated, would be the primary measure of motor clinical function. Changes in verbal fluency score is the primary measure of cognitive performance. In an exploratory manner, the connection between primary and secondary clinical outcome measures and candidate biomarkers will be investigated to determine whether candidate biomarkers are predictive of disease onset or progression.

Source link: https://clinicaltrials.gov/ct2/show/NCT01925196


HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

In this Phase I, proof-of-concept research, we want to see if an antiretroviral regimen that can be used to treat human immunodeficiency virus infection would also reduce the prevalence of Human Endogenous Retrovirus-K in a subset of patients with amyotrophic lateral sclerosis patients. We will evaluate the effectiveness of the antiretroviral therapy for people with ALS as well as the clinical and neurophysiological results of ALS symptoms, quality of life, and respiratory function. Study Population: The HERV-K:RPP30 ratio in ALS patients with a HERV-K:RPP30 ratio greater than or equal to 13. About 30% of ALS patients may have detectable levels of HERV-K; about 20% of patients with ALS have a corresponding number of > 1000 copies/ml.

Source link: https://clinicaltrials.gov/ct2/show/NCT02437110


Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

The study population included adults with clinical diagnosis of frontotemporal dementia, motor neuron disorder, or a related adult-onset neurodegenerative disorder. ALS or ALS design All participants will perform medical testing to determine diagnosis and stage disease severity, as well as a generic battery of assessments to determine cognitive and motor functions. Outcome measures Clinical results and differences among participants will be examined as part of our efforts to find common features and differences among participants.

Source link: https://clinicaltrials.gov/ct2/show/NCT03225144


An Observational Study to Assess Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing.

Object: Amyotrophic lateral sclerosis type 4 is an inherited disease of motor neuron disease caused by a mutation in the senataxin gene. Potential participants for enrollment in this study may be those with a genetic disorder identified in protocol 00-N-0043 or protocol 12-N-0095, or those who have under recent genetic testing. The scheme will encourage up to 65 people with mutation in SETX's annual review, as well as up to 50 disease control participants with mutation in other genes that change RNA processing. In addition, a maximum of 50 unrelated healthy volunteers who are age and sex matched to the enrolled ALS4 and disease control volunteers will be accepted. Study Plan: Patients with a ALS4 inherited SETX mutation will be evaluated at the NIH clinical center to identify clinical signs of the disease and collect clinical and molecular biomarkers. For a total of 4 visits, patients with ALS4 and Disease Control will report to the NIH every 12 months for scientific and molecular research. In the ALS4 group and control groups, molecular biomarkers of RNA processing will be tested to find those molecular biomarkers that are disease specific as well as those that are revealing disease progression in ALS4 ALS4. In order to determine which measurements are specific to the ALS4 disease, the molecular biomarkers from ALS4 patients will be compared to the healthy control groups and the disease control group in order to determine which measurements are specific to the ALS4 disease.

Source link: https://clinicaltrials.gov/ct2/show/NCT04394871


An Prospective Study in a Cohort of Amyotrophic Lateral Sclerosis (ALS) Patients Participating in a Phase IIb Drug Study (NCT05357950) to Evaluate the Correlation Between Oculometric Measurements and ALS Functional Rating Scale (ALSFRS-R)

This is an observational prospective study in a cohort of about 45 patients with ALS participating in the Neurosense PrimeC drug study, which is a Phase IIb, Randomized, Prospective, Double-Blind, Controlled Study, to determine PrimeC's safety, Tolerability, and Effectiveness in Subjects with ALS. The participants are males or females with no more than 30 months disease duration, who fit the inclusion criteria for the PrimeC drug research, have signed an Informed consent, and are willing and able to comply with the study's protocols, which include follow-up visits.

Source link: https://clinicaltrials.gov/ct2/show/NCT05407428

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions